UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000053714
Receipt number R000061294
Scientific Title A study on the safety and efficacy of semaglutide in obese patients
Date of disclosure of the study information 2024/02/27
Last modified on 2024/02/26 19:36:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A study on the safety and efficacy of semaglutide in obese patients

Acronym

A study on the safety and efficacy of semaglutide in obese patients

Scientific Title

A study on the safety and efficacy of semaglutide in obese patients

Scientific Title:Acronym

A study on the safety and efficacy of semaglutide in obese patients

Region

Japan


Condition

Condition

Obsesity patients

Classification by specialty

Medicine in general Endocrinology and Metabolism Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to elucidate the safety and efficacy of semaglutide injection in obese patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The change in body weight at 22-26 weeks after semaglutide.

Key secondary outcomes

The change in time in range (TIR, 70-180 mg/dL)
The change in time below range (TBR, <70 mg/dL)
The change in time below range (TBR, <54 mg/dL)
The change in time above range (TAR, >180 mg/dL)
The change in time above range (TAR, >240 mg/dL)
The change in mean sensor glucose level by CGM
The change in %CV (coefficient of variation) of sensor glucose level
The change in SD (standard deviation) of sensor glucose level
The change in glucose management indicator (GMI)
The change in glycemia risk index (GRI)
The change in the frequency of hypoglycemic events
The change in HbA1c and glycated albumin
The change in C-peptide index
The change in the dosage of insulin
The change in body composition (fat mass, muscle mass. lean body mass and waist circumference)
The change in blood pressure
The change in non-HDL cholesterol
The difference in efficacy of semaglutide between patients with and without sleep apnea


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

YES

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Semaglutide injection

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Obesity
2. Patients scheduled for semaglutide administration
3. Indications for semaglutide: Obesity, provided that the patient has hypertension, dyslipidemia, and/or type 2 diabetes, and dietary and exercise therapy alone are not enough to control body weight and metabolic disorders, limited to cases meeting the following criteria:
> BMI is 27 kg/m2 or higher and has two or more obesity-related health issues
> BMI is 35 kg/m2 or higher

Key exclusion criteria

1. Severe anemia (Hb level < 10 g/dL)
2. Patients using implanted medical devices (such as pacemakers)
3. Patients with active malignant tumors
4. Participants for whom the principal investigator or collaborating investigator has deemed participation in this clinical study inappropriate
5. Pregnant women or women who may be pregnant

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Akinori
Middle name
Last name Hayashi

Organization

Kitasato University School of Medicine

Division name

Department of Endocrinology, Diabetes and Metabolisim

Zip code

2520374

Address

1-15-1, Kitasato, Minami-ku, Sagamihara, Kanagawa

TEL

0427788111

Email

ahayashi@kitasato-u.ac.jp


Public contact

Name of contact person

1st name Akinori
Middle name
Last name Hayashi

Organization

Kitasato University School of Medicine

Division name

Department of Endocrinology, Diabetes and Metabolism

Zip code

2520374

Address

1-15-1, Kitasato, Minami-ku, Sagamihara, Kanagawa

TEL

0427788111

Homepage URL


Email

ahayashi@kitasato-u.ac.jp


Sponsor or person

Institute

Kitasato University

Institute

Department

Personal name



Funding Source

Organization

Self-funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kitasato University Medical School Ethics Committee

Address

1-15-1, Kitasato, Minami-ku, Sagamihara, Kanagawa

Tel

0427788111

Email

rinrib@med.kitasato-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2024 Year 02 Month 27 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2024 Year 02 Month 26 Day

Date of IRB


Anticipated trial start date

2024 Year 03 Month 01 Day

Last follow-up date

2026 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2024 Year 02 Month 26 Day

Last modified on

2024 Year 02 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000061294


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name